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Sirotik Hastalardaki Sağ-Sol Şant ile İlişkili Hepatopulmoner Sendromun Tanısında Makro-
Agregant Albümin Akciğer Perfüzyon Sintigrafisinin Kontrast Ekokardiyografi ile Karşılaştırılması 
ve Klinik Veriler ile İlişkisi
Objectives: The diagnosis of hepatopulmonary syndrome (HPS) which is a common complication in cirrhotic patients is still subject to debate. This 
study investigated the association of clinical findings with HPS in cirrhotic patients using macro-aggregated albumin lung perfusion scan (99mTc-
MAA lung scintigraphy). In addition, comparison between 99mTc-MAA lung scintigraphy and contrast echocardiography (CEE) in detection of HPS 
was also performed.
Methods: In this study, 27 patients with cirrhosis underwent 99mTc-MAA lung scintigraphy and contrast echocardiography comparison CEE and 
the frequency of HPS was assessed in them and also was compared across the other variables.
Results: The 99mTc-MAA lung scintigraphy showed HPS in 13 patients (48.1%) while CEE demonstrated HPS in 5 patients with cirrhosis (18.51%). 
HPS was mild in 40.74% (11/27) of the patients, and severe in only 2 patients. There was no relationship between gender, disease duration, 
having diagnosis of disease previously, pulmonary symptoms and Child-Pugh score variations and HPS (p>0.05). Comparison of hemodynamic 
indices, arterial blood gas analysis and laboratory indices between patients with and without HPS was also non-significant (p value >0.05). Among 
coagulation factors assessed in cirrhotic patients, we found only significant correlation between HPS and prothrombin time (p<0.05). 
Conclusion: HPS, particularly its mild form, is noted in a great number of patients with cirrhosis using 99mTc-MAA lung scintigraphy. Because 
of its technical ease, and possibility to obtain objective quantitative information, 99mTc-MAA lung scintigraphy can be complementary to other 
diagnostic methods in the evaluation of HPS assessment, although additional studies are needed.
Keywords: Hepatopulmonary syndrome, cirrhosis, macro-aggregated albumin lung perfusion scan, contrast echocardiography 
Abstract
Amaç: Sirotik hastalarda sık görülen bir komplikasyon olan hepatopulmoner sendromun (HPS) tanısı halen tartışmaya açıktır. Bu çalışmada, 
makroagregat albümin akciğer perfüzyon sintigrafisi (99mTc-MAA akciğer sintigrafisi) kullanılarak sirotik hastalarda klinik bulgularla HPS’nin ilişkisi 
araştırılmıştır. Ayrıca, HPS’nin saptanmasında 99mTc-MAA akciğer sintigrafisi ile kontrast ekokardiyografi (KE) karşılaştırılmıştır.
Öz
Hepatopulmonary Syndrome with Right-to-left Shunt  in Cirrhotic Patients 
Using Macro-Aggregated Albumin Lung Perfusion Scan: Comparison with 
Contrast Echocardiography and Association with Clinical Data
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Introduction
Cirrhosis is a pathologic process in which normal liver 
structure is substituted by scar tissue. Cirrhotic patients 
are vulnerable to many side effects that reduce their 
lifetime. One of these side effects is hypoxia resulting from 
hepatopulmonary syndrome (HPS) (1,2,3).
HPS, which can influence patient’s prognosis, is described 
by a clinical triad entailing being of late stage liver disease, 
gas exchange disorders, eventually leading to hypoxemia 
and the occurrence of intrapulmonary vascular dilatations 
(IPVD), without being of intrinsic pulmonary disease (4).   
Many conditions can influence the gas exchange in lungs 
(5). Ascites, pleural effusion, hepatomegaly and basal 
lung lobes atelectasis are the most common identified 
causes and can disturb oxygen exchange in a restrictive 
manner. On the other hand, some side effects of cirrhosis 
such as HPS or portopulmonary hypertension may not be 
diagnosed by physical examination, pulmonary imaging 
modalities or pulmonary function tests (6).  
In addition, increased mortality rate of cirrhotic patients 
due to HPS is reported (6).
The only method to cure this status is liver transplantation, 
so, early diagnosis of this status carries important clinically 
significance (6).
The term HPS was coined by Kennedy and Knudson 
in 1977 (7,8). Signs of HPS are dyspnea, platypnea and 
orthodeoxia and HPS is diagnosed with a clinical triad 
including chronic liver disease, increased alveolar-arterial 
gradient of O2 [p (A-a) O2] ≥15 mmHg (≥20 mmHg for 
patients over 64 years) and the presence of intrapulmonary 
right to left shunt (9,10,11).
The prevalence of this syndrome has not been completely 
understood because figures depend on the manner 
used for the identification and the characteristics of the 
population investigated (12,13).
The intrapulmonary arteriovenous shunt can be diagnosed 
by contrast enhanced echocardiography (CEE) and 99mTc-
labelled macro aggregated albumin scintigraphy (99mTc-
MAA).
Contrast CEE is considered the standard technique (14) 
which in this method, a liquid with bubbles is injected into 
a peripheral vein and the liquid entering the left cavities is 
observed withsaline bubble test.
In 99mTc-labelled macro aggregated albumin scintigraphy 
(99mTc-MAA), 99mTc labelled albumin particles are injected 
into a peripheral vein and then are capable to reach extra 
pulmonary sites like brain or kidneys parenchyma due to 
the presence of IPVD and intra pulmonary arteriovenous 
shunt (14,15,16) however, there is a doubt that in view 
of predisposing vasoconstriction in brain and kidney of 
cirrhotic patients, 99mTc-MAA scan may not be reliable in 
this setting (17). 
In current study, we evaluated cirrhotic patients to find 
the frequency of HPS in these patients with assistance of 
clinical and paraclinical methods.
Materials and Methods
In this study, we evaluated 27 cirrhotic patients referred 
to the Department of Nuclear Medicine of a University 
Affiliated Hospital between 2017-2018. 
Patients were divided into three groups based on Child-
pugh and Meld scoring systems.  The Child-pugh score 
employs five clinical measures (including total serum 
bilirubin, serum albumin, prothrombin time (PTT), ascites 
and hepatic encephalopathy) of liver disease. Each measure 
is scored 1-3, with 3 indicating most severe derangement. 
These three groups were as follow: group A (5-7), group B 
(8-9) and group C (10-15).
The Meld score is also calculated using a mathematical 
formula that is based on three laboratory results including 
total serum bilirubin, INR and SCr.
Yöntem: Bu çalışmada, sirozlu 27 hastada 99mTc-MAA akciğer sintigrafisi ve KE karşılaştırıldı ve HPS sıklığı değerlendirildi. Ayrıca HPS’nin sıklığı ile 
diğer değişkenler arasındaki ilişki araştırıldı. 
Bulgular: 99mTc-MAA akciğer sintigrafisi 13 sirozlu hastada (%48,1) HPS’nin varlığını gösterirken, KE 5 sirozlu hastada (%18,51) gösterdi. HPS 
hastaların %40,74’inde (11/27) hafif, sadece 2 hastada şiddetliydi. Cinsiyet, hastalık süresi, hastalık geçmişi, akciğer semptomları ve Child skoru ile 
HPS arasında herhangi bir ilişki yoktu (p>0,05). Hemodinamik indeksler, arteriyel kan gazı analizi ve laboratuvar indeksleri açısından HPS’li hastalar 
ve HPS’li olmayan hastalar arasında fark görülmedi (p>0,05). Sirotik hastalarda değerlendirilen koagülasyon faktörleri arasında, sadece HPS ve 
protrombin zamanı arasında anlamlı bir korelasyon bulundu (p<0,05). 
Sonuç: 99mTc-MAA akciğer sintigrafisi ile çok sayıda sirozlu hastada HPS’nin özellikle hafif formu saptandı. Teknik kolaylığı ve objektif kantitatif 
bilgi edinme olasılığı nedeniyle, 99mTc-MAA akciğer sintigrafisi HPS’nin değerlendirilmesinde diğer tanı yöntemlerini tamamlayıcı olabilir, ancak ek 
çalışmalara ihtiyaç vardır.
Anahtar kelimeler: Hepatopulmoner sendrom, siroz, makroagregat albümin akciğer perfüzyon sintigrafisi, kontrast ekokardiyografisi 
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MELD formula= 3.78×ln [serum bilirubin (mg/dL)] + 
11.2×ln (INR) + 9.57×ln [serum creatinine (mg/dL)] + 6.43.
Furthermore, we collected each patient`s clinical history of 
dyspnea and other pulmonary symptoms and we accepted 
the presence of intrapulmonary arterio venous shunt >6% 
as abnormal finding and used it for HPS diagnosis.
During the admission time, lung perfusion scintigraphy, 
echocardiography or spirometry, and laboratory tests 
including arterial blood gas (ABG), complete blood count 
and liver function tests were carried out and above 
mentioned results were compared with patient’s age, 
arterio venous shunt presence and severity of pulmonary 
failure. As mentioned above, HPS abundance was calculated 
in these cirrhotic patients.
The radionuclide study was carried out by injecting 1-4 
mCi 99mTc-MAA intravenously. In cases of intrapulmonary 
shunting as in HPS, some amount of radiotracers goes 
through the lungs into the systemic circulation like brain, 
kidneys and thyroid along with the lung. The pulmonary 
shunt percent is calculated by applying the geometric mean 
(GM) of brain and lung counts in the formula:
(GM brain) / (GM brain + GM lung ) *100 (normal <6%) 
Contrast enhanced bubble CEE  was done by agitating a 
small amount of air with saline to produce bubbles using 
a three-way stopcock, when administered into the venous 
circulation. Appearing of even one bubble in the left side 
of the heart has been considered as a criterion of right-to 
left shunting.
Moreover, all eligible participants signed an inform consent. 
This study complies with the Declaration of Helsinki, and 
it was confirmed by the Ethics Committee of Bushehr 
University of Medical Sciences. 
Statistical Analysis
Categorical variables were analyzed using chi-square test 
and continuous variables using Student’s t-test. Categorical 
values were expressed as percentage and continuous values 
were expressed as mean value ± standard deviation. Linear 
regression analysis was used to determine whether there 
was a correlation between above mentioned findings and 
HPS. P value <0.05 was considered as statically significant 
for all statistical tests. Statistical analysis was performed 
with the use of the SPSS statistical package (version 24).
Results
Our studied cirrhotic population consisted of 18 males 
(66.6%) and 9 females (33.3%), with mean age of 
52.3±17.28 years. From this population, 13 patients (10 
males and 3 females) had HPS due to the results of 99mTc-
MAA scintigraphy, therefore, 48.15% had HPS and 51.85% 
did not have HPS. HPS was mild in 40.74% (11/27) of the 
patients, and severe in only 2 patients.
In comparison, CEE demonstrated five positive shunts 
(18.51%) and the remaining did not have shunt. 
The average age of the patients with HPS was 45.5±13.43 
years and it was 58.7±18.46 years in the patients without 
HPS. There was no statistically significant difference 
between groups in terms of age (p>0.05).
There was no relationship between gender, disease 
duration, having diagnosis of disease previously, pulmonary 
symptoms (dyspnea, ortodeoxia, plathypnea and 
orthopnea) Child-pugh score variations and HPS (Table 1) 
(p>0.05).
Comparison of hemodynamic indices, ABG analysis and 
laboratory indices between patients with and without HPS 
was also non-significant (p>0.05) (Table 2,3,4).
Among coagulation factors assessed in cirrhotic patients, 
we found only significant (p<0.05) correlation between 
HPS and PTT (Table 5).
Two images of positive and negative scans for HPS are 
illustrated in Figure 1 and 2. 
Table 1. Comparison between gender, disease duration, 
having diagnosis of disease previously, pulmonary symptoms 
(dyspnea, ortodeoxia, plathypnea and orthopnea) and child 
score variations in two groups of patients with and without 
hepatopulmonary syndrome
Variation HPS+ HPS– p value
Gender
Male 44.4% 55.6%
0.695
Female 55.6% 44.4%
Disease duration
<1 year 50% 50%
1.000
>1 year 44.4% 55.6%
Having diagnosis of 
disease previously
Yes 41.2% 58.8%
0.440
No 60% 40%
Dyspnea
Yes 43.5% 56.5%
0.326
No 75% 25%
Orthodeoxia
Yes 50% 50%
1.000
No - 100%
Plathypnea
Yes 50% 50%
1.000
No - 100%
Orthopnea
Yes 45.8% 54.2%
0.596
No 66.7% 33.3%
Child-pugh score
A 35.7% 64.3%
0.180
B,C 61.5% 38.5%
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Discussion
HPS is one of the most important problems in cirrhotic 
patients. In this study, 13 (48.1%) cases with established HPS 
were detected. Moreover, there was significant correlation 
between PTT and HPS  in current study (p<0.05).
Surasi et al. (14) concluded that the 99mTc-MAA lung 
perfusion scintigraphy was helpful and could diagnose 
HPS in cirrhotic patients by finding the intrapulmonary 
arteriovenous shunt. 
El-Shabrawi et al. (15) compared the findings of contrast 
CEE and 99mTc-MAA lung perfusion scintigraphy in 40 
children with chronic liver disease and showed that 
lung perfusion scintigraphy with 99mTc-MAA was more 
sensitive than contrast CEE for determining intrapulmonary 
arteriovenous shunt in the patients with chronic hepatic 
failure. The result of that study was the same as with 
current study, in which a statistically significant difference 
between these two methods was noted.
In the current report seven patients (48.15%) demonstrated 
right to left intrapulmonary shunts shown by lung 
perfusion scintigraphy. HPS was mild in 40.74% (11/27) 
of the patients, and severe in only 2 patients.  This may be 
most likely due to the point that perfusion scintigraphy is 
able to identify trivial shunts using quantitative analysis, so 
CEE might fail to detect small shunts. Furthermore, CEE is 
also operator reliant.  
In contrary, there are a few reports showing that CEE is more 
sensitive than lung perfusion scintigraphy for the diagnosis of 
Table 2. Comparison of hemodynamic indices between 
patients with and without hepatopulmonary syndrome
Variable HPS Average SD p value
SBP
mmHg
Yes 124.6 26.8
0.57
No 120 14.3
DBP
mmHg
Yes 73.9 16.8
0.70
No 76 11.3
PR
bpm
Yes 78 11.3
0.26
No 87.8 10.4
RR
bpm
Yes 15.9 1.65
0.33
No 16.7 2.43
SBP: Systolic blood pressure, DBP: Diastolic blood pressure, PR: Pulse rate, RR: 
Respiratory rate
Table 3. Comparison of arterial blood gas analysis between 
patients with and without hepatopulmonary syndrome
Variable HPS Average SD p value
O
2
 Sat 
(%)
Yes 96.5 1.3
0.96
No 96.5 2.7
PO
2
mmHg
Yes 81.5 2.3
0.49
No 80.7 3.2
PH
Yes 7.37 0.038
0.47
No 7.38 0.025
PCO
2
mmHg
Yes 45.6 6.3
0.22
No 42.6 4.8
HCO
3
Yes 26.6 5.2
0.38
No 25.1 2.5
Table 4. Comparison of laboratory indices between 
patients with and without hepatopulmonary syndrome
Variable HPS Average SD p value
Hb
g/dl
Yes 11.2 2.7
0.86
No 11.2 2.3
Albümin
g/L
Yes 3.5 0.7
0.98
No 3.5 0.6
AST
U/l
Yes 49.5 32.4
0.64
No 57.5 53.1
ALT
U/l
Yes 39.8 36.2
0.92
No 41.3 37.2
ALP
U/l
Yes 267.1 92.2
0.72
No 295.4 193.7
Na+
mEq/L
Yes 138.5 2.4
1.00
No 138.5 2.3
Bilirubin
mg/dL
Yes 2.2 0.8
0.76
No 1.9 0.5
Serum creatinine
mg/dL
Yes 1.1 0.5
0.63
No 1.04 0.3
HPS: Hepatopulmonary syndrome, Hb: Hemoglobin, SD: Standard deviation, AST: 
Aspartat aminotransferaz, Alb: Albumin
Table 5. Comparison of coagulation factors between 
patients with and without hepatopulmonary syndrome
Variable HPS Average SD P value
Platelet count Yes 117.4 64.5 0.77
No 124.7 65.1
PT seconds Yes 13.2 1.3 0.09
No 16.5 6.8
PTT
seconds
Yes 33.8 12.8 0.04
No 53.2 28.1
INR Yes 1.2 0.2 0.07
No 1.5 0.5
PTT: Partial thromboplastin time, PT: Prothrombin time, INR: International 
normalized ratio, SD: Standard deviation, SD: Standard deviation
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intrapulmonary shunting (9). In addition, CEE can be done as 
a part of standard echocardiographic screening for pulmonary 
hypertension and the European Respiratory Society Task Force 
on Pulmonary-hepatic vascular diseases has advised CEE as 
the first step method in screening of HPS (8).
In another study done by Grimon et al. (17), 135 
children with chronic hepatic failure were evaluated and 
they delineated that 99mTc-MAA scintigraphy was more 
accurate than ABG analysis in detection of intrapulmonary 
arteriovenous shunt. Although we found the same result, 
there was no correlation between ABG indices and HPS.  
Likewise, Fatemi et al. (18) worked on 54 cirrhotic patients 
and showed that 10 patients had the clinical criteria of 
HPS and 7 patients had sub-clinical criteria of HPS. Their 
rate was  less than our rate of 48%. In their study, the 
most prevalent clinical signs were dyspnea and cyanosis. 
Dyspnea had high sensitivity and achropachy had high 
specificity in cirrhotic patients with HPS.
On the other hand , PO
2
<70 and alveolar-arterial gradient 
had the highest sensitivity in this era (19) however, we did 
not find any relationship between these laboratory indices 
and HPS. 
Fragaki et al. (20) assessed HPS in cirrhotic patients using 
99mTc-MAA lung scintigraphy and correlated the results with 
clinical data. In total, 94 out of 102 included patients had 
complete scintigraphic data. Overall, 24 (26%) patients had 
HPS and 95.8% of them had mild-to-moderate HPS. There 
was no significant difference in terms of HPS between 
decompensated (24.6%) and compensated cirrhosis 
(27.3%). In the multivariate analysis, only the quantitative 
index was noteworthy for the identification of HPS. They 
concluded that mild-to moderate HPS had no substantial 
effect on survival of cirrhotic patients. Also in our study, 
most of the detected HPS was mild (40.74%). 
In contrast to our finding, Grilo et al. (21) who assessed 
99mTc-MAA lung perfusion scan in 115 cirrhotic subjects 
with HPS candidates for liver transplantation, demonstrated 
that the 99mTc-MAA had a low sensitivity  for the diagnosis 
of HPS. 
However, it should be noted that 99mTc-MAA lung 
scintigraphy as compared with CEE, has  disadvantages 
of underestimation of intrapulmonary shunt fraction in 
advanced liver disease because of renal and cerebral 
arterial vasoconstriction occurring  in patients with cirrhosis 
which increases with progression of the liver disease (16). 
In addition, 99mTc-MAA lung scintigraphy depicts total value 
of right to left shunt, which may be due to cardiac problem 
in origin, so performance of CEE can assess one-stop shop. 
This study suffered from some demerits; the most important 
ones were a small overall sample of participating patients, 
and lack of follow up to assess the survival analysis. 
Therefore, further research necessitates a larger number of 
patients split into more categories of HPS to find the best 
clinical outcomes. 
Figure 2. Hepatopulmonary syndrome: 99mTc-MAA is accumulated in the 
lungs, and brain (shunt=26%)
Figure 1. Normal scanning: 99mTc-MAA is only accumulated in the lungs 
(shunt=1%)
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Conclusion
HPS, particularly its mild form is noted in a great number of 
patients with cirrhosis using 99mTc-MAA lung scintigraphy. 
Because of its technical ease, and possibility to obtain 
objective quantitative information, 99mTc-MAA lung 
scintigraphy can be complementary to other diagnostic 
methods in the evaluation of HPS assessment, although 
additional studies are needed.
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